Effi cacy of the Combination of Tetracycline, Amoxicillin, and Lansoprazole in the Eradication of Helicobacter pylori in Treatment-Naïve Patients and in Patients Who Are Not Responsive to Clarithromycin-Based Regimens: A Pilot Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The aim of this study was to evaluate the eradication rate of a triple therapy regimen that included a proton pump inhibitor, amoxicillin, and tetracycline instead of clarithromycin in treatment-naïve patients and in patients who did not respond to standard triple therapy. Methods: This study included 110 patients infected with Helicobacter pylori. Patients in groups A and B were treatment-naïve, and those in group C were not responsive to previous standard triple therapy. Patients in group A (n=40) received lansoprazole 30 mg b.i.d., amoxicillin 1,000 mg b.i.d., and clarithromycin 500 mg b.i.d. for 14 days. Patients in groups B (n=40) and C (n=30) received lansoprazole 30 mg b.i.d., amoxicillin 1,000 mg b.i.d., and tetracycline 500 mg q.i.d. for 14 days. Results: In group A, eradication was achieved in 18 (45%) of the 40 patients included in the intention-to-treat (ITT) analysis and in 18 (47.4%) of the 38 patients included in the per-protocol (PP) analysis. In group B, eradication was achieved in 15 (37.5%) of the 40 patients included in the ITT analysis and in 15 (39.3%) of the 38 patients included in the PP analysis. In group C, eradication was achieved in 14 (46.6%) of the 30 patients included in the ITT analysis and in 14 (43.8%) of the 29 patients included in the PP analysis. There was no statistically signifi cant difference among the 3 groups with regard to eradication rates (p>0.05). Conclusions: Despite the low rate of resistance to tetracycline, the combination of lansoprazole, amoxicillin, and tetracycline instead of clarithromycin is not a good option for the eradication of H. pylori.
Abstract
Background/Aims: The aim of this study was to evaluate the eradication rate of a triple therapy regimen that included a proton pump inhibitor, amoxicillin, and tetracycline instead of clarithromycin in treatment-naïve patients and in patients who did not respond to standard triple therapy. Methods: This study included 110 patients infected with Helicobacter pylori. Patients in groups A and B were treatment-naïve, and those in group C were not responsive to previous standard triple therapy. Patients in group A (n=40) received lansoprazole 30 mg b.i.d., amoxicillin 1,000 mg b.i.d., and clarithromycin 500 mg b.i.d. for 14 days. Patients in groups B (n=40) and C (n=30) received lansoprazole 30 mg b.i.d., amoxicillin 1,000 mg b.i.d., and tetracycline 500 mg q.i.d. for 14 days. Results: In group A, eradication was achieved in 18 (45%) of the 40 patients included in the intention-to-treat (ITT) analysis and in 18 (47.4%) of the 38 patients included in the per-protocol (PP) analysis. In group B, eradication was achieved in 15 (37.5%) of the 40 patients included in the ITT analysis and in 15 (39.3%) of the 38 patients included in the PP analysis. In group C, eradication was achieved in 14 (46.6%) of the 30 patients included in the ITT analysis and in 14 (43.8%) of the 29 patients included in the PP analysis. There was no statistically signifi cant difference among the 3 groups with regard to eradication rates (p>0.05). Conclusions: Despite the low rate of resistance to tetracycline, the combination of lansoprazole, amoxicillin, and tetracycline instead of clarithromycin is not a good option for the eradication of H. pylori.
참고문헌 (21)
- Marshall BJ, "The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer", JAMA, 274, pp.1064~1066 (1995)
- Parsonnet J, "Helicobacter pylori infection and gastric lymphoma", N Engl J Med, 330, pp.1267~1271 (1994)
- Blaser MJ, "Helicobacter pylori genetic diversity and risk of human disease", J Clin Invest, 107, pp.767~773 (2001)
- Wilkinson M, "Helicobacter pylori: an overview", Br J Biomed Sci, 58, pp.59~60 (2001)
- Eslick GD, "Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis", Am J Gastroenterol, 94, pp.2373~2379 (1999)
- Suerbaum S, "Helicobacter pylori infection", N Engl J Med, 347, pp.1175~1186 (2002)
- Kearney DJ, "Retreatment of Helicobacter pylori infection after initial treatment failure", Am J Gastroenterol, 96, pp.1335~1339 (2001)
- Kadayifçi A, "Efficacy of a proton pump inhibitor plus amoxicillin plus clarithromycin in the eradication of H. pylori in Turkey: a meta-analysis", Turk J Gastroenterol, 15(Suppl 1), pp.5~ (2004)
- Güliter S, "Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of Helicobacter pylori?", Turk J Gastroenterol, 16, pp.29~33 (2005)
- Katzung BG, "Basic & clinical pharmacology", pp.726~771 (2006), McGraw Hill
- Guidelines for the management of Helicobacter pylori infection: summary of the Maastricht-3 2005 Consensus Report. European Gastroenterology Review 2005, "Malfertheiner P", Touch Briefings, ~ (2005)
- Moder KA, "Rapid screening of clarithromycin resistance in Helicobacter pylori by pyrosequencing", J Med Microbiol, 56(Pt 10), pp.1370~1376 (2007)
- Wu JY, "Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes", Antimicrob Agents Chemother, 49, pp.578~583 (2005)
- Peren H. Baglan, "Clarithromycin Resistance Prevalence and Icea Gene Status in Helicobacter Pylori Clinical Isolates in Turkish Patients with Duodenal Ulcer and Functional Dyspepsia", The Journal of Microbiology, 44(4), pp.409~416 (2006), 한국미생물학회
- Toracchio S, "Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002", Dig Liver Dis, 35, pp.541~545 (2003)
- Göral V, "Antibiotic resistance in Helicobacter pylori infection", T Klin Gastroenterohepatol, 11, pp.87~92 (2000)
- Bakir Ozbey S, "Antibiotic resistance rates of Helicobacter pylori isolates and the comparison of E-test and fluorescent in situ hybridization methods for the detection of clarithromycin resistant strains", Mikrobiyol Bul, 43, pp.227~234 (2009)
- Gumurdulu Y, "Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey", World J Gastroenterol, 10, pp.668~671 (2004)
- Aydın A, "Efficacy of pantoprazole plus amoxicillin plus clarithromycin for 1 week and 2 weeks in the eradication of clarithromycin-sensitive and clarithromycinresistant H. pylori", Turk J Gastroenterol, 15(Suppl 1), pp.151~ (2004)
- Matsumoto Y, "Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan", Dig Liver Dis, 37, pp.821~825 (2005)
- Perri F, "Randomized study of different ‘second-line’ therapies for Helicobacter pylori infection after failure of the standard ‘Maastricht triple therapy’", Aliment Pharmacol Ther, 18, pp.815~820 (2003)